The Sage Group peripheral arterial and venous disease

REPORTS
(Organized with Most Recent Publications First)

India Peripheral Arterial Disease, Thromboangiitis Obliterans & Critical Limb Ischemia Epidemiology and Markets
Additional Information

Peripheral Arterial Disease (PAD) Interventional Market Analysis 
Based on Treatment with Angioplasty or Atherectomy
Additional Information

Critical Limb Ischemia
Volume II Western Europe Epidemiology
Additional Information

Peripheral Arterial Disease
Coding and Reimbursement 2008
Additional Information

Intermittent Claudication Europe. A Country-Specific Market Analysis of Oral IC Therapies and A Population-Based Analysis of the Potential Market 2007-2020
Additional Information

Peripheral Arterial Disease - New Pharmaceutical Therapies to Treat Intermittent Claudication Symptoms, Prevent Ischemic Events and to Induce Angiogenesis
Additional Information

Peripheral Arterial Disease (PAD) Interventional Market Analysis 
Primary and Provisional Stenting
Additional Information

Peripheral Arterial Disease (PAD) Interventional Market Analysis 
Based on Potential Treatment with Perioperative Oral Antiplatelet Therapy       
Additional Information

Critical Limb Ischemia
Volume I United States Epidemiology
Additional Information

Acute Limb Ischemia (ALI)
A Market of Multiple Therapies and Multiple Procedures
Additional Information

Volume II
Peripheral Arterial Disease
A Significant Opportunity for Interventional Therapies
Additional Information


Volume I
Peripheral Arterial Disease
Underestimated, Underdiagnosed and Undertreated
A Significant Opportunity for Drug Therapies
Additional Information

 Reports By Topic  

.

 

NEW REPORT

Peripheral Arterial Disease Interventi0nal Market Analysis Based on Treatment with Angioplasty or Atherectomy

Additional Information

According to THE SAGE GROUP, Peripheral Arterial Disease represents a sizeable and rapidly growing market opportunity for angioplasty and atherectomy devices. Projected market expansion reflects an increasing number of patients diagnosed and treated, as well as new technologies replacing other therapies.  

 

Our research indicates that femoropopliteal (above knee) disease represents the largest single opportunity for new endovascular devices with procedures forecast to expand to over 1.7 million by 2020. Although much smaller in terms of total procedures, the tibioperoneal (below knee) market is forecast to grow at an extremely rapid pace and exceed 390,000 procedures by 2020.

 

.